The EVAHEART 2 left ventricular assist device is meant as either a long-term therapy or as a bridge to heart transplant. It reduces some of the risks associated with standard LVADs, such as stroke and gastrointestinal bleeding, according to the news release.
Richard Huggins, 75, a resident of Lock Haven, Pa., became the second patient in the U.S. to undergo the procedure Jan. 14 at the hospital.
The treatment is part of an ongoing clinical study assessing the use of the device across 40 clinical sites. It involves 399 severe heart failure patients and will continue through 2022.
More articles on cardiology:
U of Arkansas for Medical Sciences names director of interventional cardiology
American Heart Association names latest addition to top mitral valve surgery program list
USF Health, Tampa General Hospital 1st in state to introduce novel central sleep apnea procedure
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
